Mon, Dec 22, 2014, 12:44 PM EST - U.S. Markets close in 3 hrs 16 mins

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • durban500 durban500 Dec 10, 2011 2:54 PM Flag

    Longs Shorts and in Betweens

    Surprisingly the shorts here have a real lack of understanding of the deeper clinical issues at play. I say surprisingly because the shorts usually do their homework and a position this large should not be dismissed.

    Shorts know that ABVD is cheap and effective (90%+ cure) so they believe that there is no place in a first line setting for adcetris. What they don't understand is the huge interest in reducing the long term health effects of current treatment. The 20 year old Hodgkin patient (and there are plenty of them) will eventually become the 40 year old heart failure or pulmonary failure patient (bleomycin). These so called "late effects" are a known problem. The interest in reducing them can't be understated. If it is as effective as current standard treatment, adcetris use will explode.

 
SGEN
32.5972-0.2928(-0.89%)12:44 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.